false
0001527728
0001527728
2025-10-15
2025-10-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the
Securities ExchangeAct of 1934
Date of Report (Date of earliest event
reported): October 15, 2025
LUNAI
BIOWORKS, INC.
(Exact name of
registrant as specified in its charter)
| Delaware |
|
001-38751 |
|
45-2259340 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
2080
Century Park East, Suite 906
Los Angeles, CA 90067
(Address of principal executive
offices)
+1 (305) 918-1980
(Registrant’s
telephone number, including area code)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant
under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant
to Section 12(b) of theAct:
| Title
of Each Class |
|
Trading
Symbol |
|
Name of
Each Exchange on Which Registered |
| Common Stock, par value $0.0001 per share |
|
LNAI |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether
the registrant is an emerging
growth company as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities ExchangeAct of 1934
(§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company,
indicate by check mark if the registrant has elected
not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the ExchangeAct. ☐
Item 3.01 Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On October
15, 2025, Lunai Bioworks (the “Company”) received a Notice from the NASDAQ Stock Market that the Company has regained compliance
with Listing Rule 5550(a)(2). On April 14, 2025, the NASDAQ staff notified the Company that its common stock failed to maintain
a minimum bid price of $1.00 over the previous thirty (30) consecutive business days as required by the Listing Rules of the NASDAQ Stock
Market. Since then, the staff of NASDAQ has determined that for the last eleven (11) consecutive business days from September 30,
2025 to October 14, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater.
Item 9.01 Financial Statements
and Exhibits.
A Press Release announcing compliance with the Listing
Rule was published by the Company on October 16, 2025, a copy of which is filed herewith as Exhibit 99.1
Exhibit Index
| Exhibit No. |
Description |
| |
|
| 99.1 |
Press Release Announcing Compliance with the List Requirements dated October 16, 2025. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
LUNAI BIOWORKS, INC. |
| |
|
| |
By: |
/s/ David Weinstein |
| |
Name: David Weinstein |
| |
Title: Chief Executive Officer |
| |
|
| Date: October 16, 2025 |
|
